Sermorelin and blood work: what gets tested and why

Last updated 2026-07-24

What blood tests do you actually need before starting sermorelin?

A reasonable baseline panel before starting sermorelin includes IGF-1, a metabolic panel (glucose, sometimes HbA1c), thyroid function, and a look at pituitary-adjacent hormones if your prescriber suspects a broader hormone problem rather than isolated GH decline. Some clinicians also pull a lipid panel, since GH status affects lipid metabolism, and a basic CBC as general health screening. IGF-1 (insulin-like growth factor 1) is the number that matters most. Growth hormone itself pulses through the blood in short bursts and is nearly impossible to interpret from a single draw. IGF-1, made mainly by the liver in response to GH, stays much more stable over 24 hours, which is why it's the standard proxy clinicians use to judge whether the GH axis is working. Sermorelin works by stimulating the pituitary to release GH via the GHRH receptor, so checking IGF-1 tells you whether that stimulation is translating into more hormone downstream ^[1]. If there's a real concern about pituitary disease rather than just age-related decline, your prescriber may also want imaging or a formal GH stimulation test done in a clinical setting, more than sermorelin as a trial. That's a different workup than what a typical sermorelin patient needs, but it's worth flagging if your history includes head trauma, radiation, or pituitary tumor risk factors.

Does sermorelin show up on a blood test?

Not on any test your doctor's office runs. Sermorelin itself is a short synthetic peptide (the bioactive fragment of growth hormone releasing hormone, GHRH 1-29) with a short half-life in circulation, and detecting it directly requires specialized mass spectrometry methods developed mainly for anti-doping labs, not standard clinical chemistry ^[2]. Researchers have built several of these detection methods, including antibody-based immunoaffinity purification followed by LC-HRMS/MS that can find GHRH-related peptides in plasma or urine down to low picogram-per-milliliter concentrations ^[3][4], and newer antibody-free ultrafiltration approaches meant to simplify that workflow ^[5]. There's also work comparing magnetic bead chemistries used to pull these peptides out of plasma before analysis ^[6], and capillary electrophoresis methods built specifically to separate enantiomeric GHRH analogs ^[7]. None of that is what your primary care doctor or endocrinologist is ordering. This infrastructure exists almost entirely for sports anti-doping surveillance, because GHRH analogs are prohibited in competitive sport, not for routine patient monitoring ^[8]. So practically: a regular lab draw won't detect sermorelin use, and there's no clinical reason to test for it directly. What your prescriber cares about is the effect, IGF-1 rising, not the peptide's presence.

What is IGF-1 and why does it matter more than GH?

IGF-1 is a peptide hormone the liver produces largely in response to growth hormone signaling, and it circulates at fairly stable levels rather than spiking and crashing the way GH does. That stability is exactly why it's the workhorse lab value in GH axis management. A study in hypogonadal men treated with growth hormone secretagogues (a category that includes GHRH analogs like sermorelin) found that treatment raised serum IGF-1 levels, and the paper's authors used that IGF-1 change as their primary marker of biological effect ^[9]. That's the same logic applied in sermorelin dosing generally: you're not trying to catch a GH pulse, you're watching the trend line of IGF-1 over weeks. IGF-1 reference ranges are age- and sex-adjusted, and labs report them that way because normal IGF-1 in a 25-year-old looks abnormally low in a 60-year-old and vice versa. Bring your prescriber the actual reference range from your specific lab report rather than comparing your number to a friend's, since assay methods differ between laboratories.

When should you get labs checked after starting sermorelin?

A common pattern is baseline labs before the first dose, a recheck around 6 to 12 weeks after starting (long enough for IGF-1 to reflect a new steady state), and then periodic monitoring every 3 to 6 months if you continue treatment. Nobody has published a single official monitoring schedule specific to off-label adult sermorelin use, so this cadence comes from general endocrine practice around GH-axis therapies rather than from a dedicated sermorelin trial protocol. The original clinical literature on sermorelin comes largely from its use in children with idiopathic growth hormone deficiency, where it was studied both as a diagnostic stimulation test and as a treatment, with growth velocity and IGF-1 response tracked over months of therapy ^[10]. Adult use, mostly for adult-onset GH insufficiency or age-related decline, borrows that monitoring logic but applies it more loosely ^[11]. If your IGF-1 isn't moving after a couple of months at a stable dose, that's useful information, not necessarily a failure. It might mean the dose needs adjusting, the injection technique or timing needs a look, or that your particular physiology isn't responding much to GHRH stimulation. Compare where you started against sermorelin peptide before and after accounts, but treat individual results as anecdotal, not proof of a typical outcome.

How is sermorelin different from HGH for blood work and monitoring?

This is the real fork in the road for most people considering either option, and blood work is one of the clearest ways to see the difference. HGH (recombinant human growth hormone, sold under approved brand names and reviewed in the FDA's Drugs@FDA database ^[12]) is the hormone itself, injected directly. It bypasses the pituitary. Sermorelin is GHRH, a signal that tells your own pituitary to make and release its own GH, which means your pituitary has to be capable of responding for sermorelin to do anything.

Is sermorelin FDA-approved, and does that affect who prescribes it or how it's monitored?

Sermorelin was previously sold in the United States under the brand name Geref, an FDA-approved product. Geref was discontinued by its manufacturer for business reasons; it was not pulled for a safety problem. That's a meaningful distinction, because it means sermorelin has real US regulatory history and clinical trial data behind it, something most compounded peptides on the market never had. Today, sermorelin used in the US is typically compounded rather than dispensed as an FDA-approved commercial product, since the original branded version is no longer marketed. Compounded medications fall under a different regulatory framework: 21 U.S.C. 353a governs traditional pharmacy compounding ^[13], and FDA maintains lists of bulk drug substances that can be used in compounding under section 503A ^[14] and 503B ^[15]. Whether a specific peptide is compoundable in a given state depends on those lists and on state board of pharmacy rules, and that list changes, so check current status rather than assuming. This regulatory setup means sermorelin monitoring isn't standardized the way it would be for an FDA-approved drug with an official package insert dosing and monitoring schedule. You're relying on your prescriber's clinical judgment and general endocrine practice patterns, not a manufacturer label. That's not necessarily worse, but it is different, and it's part of why choosing a provider-reviewed route with actual lab follow-up matters more here than for a conventional approved drug.

What do abnormal or unexpected lab results on sermorelin usually mean?

An IGF-1 that comes back below the expected range after weeks of sermorelin use might mean the dose is too low, injections are being missed or timed poorly, or the pituitary simply isn't very responsive to GHRH stimulation in your case. It's not automatically dangerous, but it is a signal that the current approach isn't achieving its stated goal. An IGF-1 that comes back unexpectedly high deserves more attention. Very high IGF-1 raises questions about acromegaly-type overstimulation, dosing errors, or in rare cases something unrelated to the sermorelin at all, like an underlying pituitary tumor that predates treatment. A long-term GH user case report described anterior cervical osteophyte-related dysphagia, a mechanical throat problem tied to bone changes from prolonged elevated GH exposure, illustrating that sustained overexposure to the GH-IGF-1 axis carries real, if uncommon, structural risks worth taking seriously ^[16]. That case involved GH use broadly, not sermorelin specifically, but it's a reasonable reason to not treat IGF-1 monitoring as optional busywork. Glucose and HbA1c changes are the other thing to watch. GH and IGF-1 both interact with insulin sensitivity, so metabolic labs matter alongside IGF-1, not instead of it. If your fasting glucose creeps up after starting sermorelin, that's worth a conversation, not something to shrug off.

Are there other tests researchers use for sermorelin besides IGF-1?

In research and forensic settings, yes, but they're not something a clinic patient needs. Anti-doping and analytical chemistry labs have built an entire toolkit for finding GHRH peptides directly in biological samples, mostly because GHRH analogs are banned in competitive sport and testers need methods to catch use that a hormone-level blood panel alone would miss. Those methods include LC-MS/MS approaches tuned for urine ^[4][17], cationic exchange solid-phase extraction combined with triple quadrupole UHPLC-MS/MS ^[18], and techniques designed to handle the fact that GHRH-related peptides degrade relatively quickly once outside the body, which required researchers to build in-house reference standards just to study how these peptides break down in serum and via enzymatic action ^[19]. A 2021 review specifically covered advances in detecting GHRH synthetic analogs, tracking how testing methods evolved as new analogs appeared ^[2]. None of this changes what you, as a patient, get tested for. It exists because sermorelin and related GHRH peptides sit at the intersection of legitimate endocrine medicine and performance-enhancement misuse, and regulators need ways to tell the two apart in elite sport. A 2026 review on performance-enhancing peptides modulating the GH-IGF-1 axis specifically discusses the gap between what's been clinically validated and what's being self-administered outside medical supervision ^[20], which is a good reminder that patient context, meaning a prescriber who's actually reviewing your labs, is the thing separating legitimate use from the gray-market version.

What does current research actually say about sermorelin's effectiveness and safety, based on blood markers?

The evidence base is real but limited in scope, and it's worth being honest about what it does and doesn't cover. A 2006 review specifically framed sermorelin as a possible better-tolerated approach to adult-onset GH insufficiency compared to other options available at the time, largely because it preserves physiologic pulsatile release rather than delivering a flat GH dose ^[1]. That's a fair characterization of the theoretical advantage, not proof of superior long-term outcomes. A 2020 paper on growth hormone secretagogues in hypogonadal men specifically discussed their role in body composition management, situating GHRH-based approaches as an adjunct consideration alongside androgen therapy rather than a replacement for it ^[11]. Separately, a 2017 study found that growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels, using that lab change as its key outcome measure ^[9], which again reinforces that IGF-1 is the metric researchers themselves rely on. More recent orthopedic and sports medicine literature has looked at therapeutic peptides broadly, including GHRH analogs, and flagged both real potential and real gaps: a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews covered applications and challenges of therapeutic peptides including sermorelin-class compounds ^[21], while a 2026 Sports Medicine paper specifically evaluated safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance, a useful reminder that a lot of peptide use in that world runs ahead of the evidence ^[22]. There's also isolated exploratory work, like a 2021 paper proposing sermorelin as a potentially effective drug for recurrent glioma ^[23], which is interesting mechanistically but has nothing to do with typical adult GH-support use and shouldn't be read as evidence for anything beyond that narrow research question.

How does sourcing and compounding quality affect your blood work results?

If the sermorelin you're injecting is under-dosed, contaminated, or degraded, your IGF-1 response can look flat even though you're doing everything else right, which is why sourcing matters as much as dosing schedule. GHRH-related peptides are known to be enzymatically fragile; researchers studying their stability in serum have had to characterize degradation profiles just to build reliable reference standards for lab testing ^[19]. If a peptide degrades quickly under controlled lab conditions, it's reasonable to worry about a poorly stored or poorly compounded vial doing the same thing before it ever reaches your bloodstream. A 2016 investigation into falsified biopharmaceutical injectables in Europe is a sobering reminder that the injectable peptide and biologic supply chain has a real counterfeit and quality problem, not a hypothetical one ^[24]. This is the practical argument for sourcing through a provider-reviewed pathway rather than an unregulated online seller: your prescriber can correlate a flat or unexpected IGF-1 result with a product quality issue, adjust accordingly, and coordinate with a legitimate compounding pharmacy rather than leaving you guessing whether the problem is your body or your vial. Sermorelin Co's provider-reviewed route connects patients with prescribers who order the follow-up labs and work with a fulfilling pharmacy partner on the compounding side, rather than leaving sourcing and monitoring to guesswork. If you're comparing options, best place to buy sermorelin and sermorelin reviews are worth reading before you commit to a source.

Can you combine sermorelin with other peptides, and does that change your blood work needs?

Some prescribers pair sermorelin with other GH-axis peptides, most commonly a GHRP (growth hormone releasing peptide) or, less commonly, tesamorelin, which is itself a GHRH analog with FDA approval for a specific indication (HIV-associated lipodystrophy) unrelated to typical off-label sermorelin use. Combining two agents that both push on the GH-IGF-1 axis makes IGF-1 monitoring more important, not less, since the combined effect can push levels higher than either agent alone would. If you're considering that route, read can stack tesamorelin and sermorelin for a fuller comparison of how the two agents differ mechanistically and what that means for combined dosing. The short version for blood work purposes: more agents pushing the same pathway means your prescriber needs a clearer baseline and closer follow-up, not a looser one.

What should you ask your prescriber about blood work before starting sermorelin?

Ask what your baseline IGF-1 and metabolic labs show relative to your age-adjusted reference range, when they plan to recheck after starting, and what specific number or trend would make them adjust your dose or stop treatment. Ask whether they're also screening for thyroid and glucose issues, since those interact with the GH axis and can confound how you interpret IGF-1 changes. Also worth asking directly: what happens if IGF-1 doesn't move after two or three months. A prescriber with real experience should have a clear answer, whether that's a dose adjustment, a switch to a different approach, or an honest conversation that sermorelin may not be right for your physiology. If you want the fuller safety picture before that conversation, sermorelin long-term side effects is a good next read, and pairing that with your own lab trend over time is the most honest way to judge whether treatment is doing anything for you at all.

Frequently asked questions

Does sermorelin show up on a standard blood test?

No. Standard clinical blood panels don't test for sermorelin itself. Detecting the peptide directly requires specialized mass spectrometry methods used mainly in anti-doping labs, not routine clinical chemistry. What your doctor actually checks is IGF-1, the downstream hormone that reflects whether sermorelin is stimulating your pituitary to release more growth hormone.

What blood test shows if sermorelin is working?

IGF-1 (insulin-like growth factor 1) is the standard marker. Growth hormone itself pulses too briefly to measure reliably, so clinicians track IGF-1, which stays more stable and rises in response to increased GH output. A rising IGF-1 trend over several weeks is the usual sign that sermorelin is having an effect.

How soon after starting sermorelin should I get blood work done?

A common approach is baseline labs before starting, then a recheck around 6 to 12 weeks in, once IGF-1 has had time to reach a new steady state. There's no single official schedule for adult off-label use, so exact timing varies by prescriber and should be discussed directly with yours.

Is sermorelin the same as HGH on a blood test?

No. HGH is the hormone itself, given directly. Sermorelin is GHRH, a signal that tells your own pituitary to make and release GH. Both are monitored mainly through IGF-1 levels, but sermorelin only works if your pituitary can still respond, while HGH bypasses the pituitary entirely.

Was sermorelin ever FDA-approved?

Yes. It was sold in the US under the brand name Geref, an FDA-approved product. Geref was discontinued by its manufacturer for business reasons, not pulled for a safety failure. Sermorelin used today is typically compounded rather than sold as that original branded product.

Can a high IGF-1 on sermorelin be dangerous?

Very high IGF-1 deserves attention. It can signal overstimulation, a dosing problem, or in rare cases an unrelated pituitary issue. Long-term excess GH-axis activity has been linked to structural problems in case reports, including one describing throat-related bone changes in a long-term GH user, so unusually high results shouldn't be ignored.

What baseline labs should I get before starting sermorelin?

A reasonable baseline includes IGF-1, a metabolic panel with glucose, thyroid function tests, and sometimes a lipid panel and CBC as general health screening. Some prescribers add more depending on your history, especially if pituitary disease is a real possibility rather than routine age-related decline.

Why does sermorelin monitoring focus on IGF-1 instead of growth hormone itself?

Growth hormone is released in short pulses throughout the day, making a single blood draw nearly meaningless. IGF-1, produced by the liver in response to GH, circulates at much more stable levels over 24 hours, which is why it's the practical marker clinicians and researchers rely on.

Do I need blood work if I combine sermorelin with another peptide like tesamorelin?

Yes, arguably more than with sermorelin alone. Combining two agents that both push on the GH-IGF-1 axis can raise IGF-1 further than either alone, so closer baseline and follow-up monitoring makes sense. Discuss combined dosing and monitoring plans directly with your prescriber before starting.

Can compounding quality affect my blood work results on sermorelin?

Yes. GHRH-related peptides are enzymatically fragile and can degrade with poor storage or manufacturing. A flat IGF-1 response despite consistent dosing can reflect a quality problem with the compounded product, not a failure of the therapy itself, which is one reason sourcing through a reviewed pharmacy pathway matters.

Does insurance or a lab require special testing to prescribe sermorelin?

There's no universal requirement, since sermorelin is generally used off-label and compounded rather than dispensed as an FDA-approved product with a standard label. Individual prescribers set their own baseline and follow-up lab requirements based on clinical judgment rather than a fixed regulatory mandate.

How is sermorelin regulated differently from HGH for sourcing?

Multiple recombinant HGH products remain FDA-approved and listed in the Drugs@FDA database. Sermorelin's original approved product, Geref, is discontinued, so current sermorelin is typically compounded under frameworks like 21 U.S.C. 353a and FDA's 503A and 503B bulk substance lists, a different regulatory path than an approved commercial drug.

Sources

1. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin is framed as a potentially better-tolerated approach to adult-onset GH insufficiency partly because it preserves physiologic pulsatile GH release.
2. Drug Testing and Analysis, 2021 (PMID 34665524): Review tracking advances in detection methods for GHRH synthetic analogs as new analogs emerged.
3. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Immunoaffinity purification combined with LC-HRMS/MS was used to qualitatively identify GHRHs in human plasma.
4. Journal of Mass Spectrometry, 2024 (PMID 38197510): Chromatographic-mass spectrometric methods were developed to analyze peptidic analytes between 2-10 kDa in doping control urine samples.
5. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): An antibody-free, ultrafiltration-based nanoLC-HRMS/MS assay was developed to detect GHRHs in urine at low pg/mL concentrations.
6. Journal of Chromatography A, 2020 (PMID 32971474): Study compared magnetic bead surface functionalities for immunopurification of GHRHs prior to LC-HRMS analysis.
7. Electrophoresis, 2023 (PMID 36787346): Capillary electrophoresis method developed for separation of enantiomeric GHRH analogs using large volume sample stacking preconcentration.
8. The Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Review of peptide and peptide-analog drug use in recreational and professional sport, framing why GHRH detection infrastructure exists mainly for anti-doping purposes.
9. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels, used as the study's key outcome measure.
10. BioDrugs, 1999 (PMID 18031173): Review of sermorelin's use in diagnosis and treatment of children with idiopathic growth hormone deficiency, tracking IGF-1 and growth velocity response.
11. Translational Andrology and Urology, 2020 (PMID 32257855): Discusses the role of growth hormone secretagogues in managing body composition in hypogonadal men alongside androgen therapy.
12. FDA, Drugs@FDA database: Multiple recombinant HGH products remain FDA-approved and listed, unlike sermorelin's discontinued Geref.
13. 21 U.S.C. 353a, pharmacy compounding: Governs traditional pharmacy compounding, the framework under which sermorelin is typically prepared since its branded product was discontinued.
14. FDA, bulk drug substances used in compounding under section 503A: FDA maintains lists of bulk drug substances permitted for use in compounding under section 503A.
15. 21 CFR 216.24, the 503B Bulks List: Sets out the bulk drug substances list applicable to 503B outsourcing facility compounding.
16. Frontiers in Surgery, 2026 (PMID 42465868): Case report describes anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating structural risk from sustained GH-axis overexposure.
17. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): Nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry was developed to analyze GHRH and its analogs in urine.
18. Analytical Biochemistry, 2023 (PMID 37806509): Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS was developed to detect GHRHs in urine samples.
19. Biomedical Chromatography, 2023 (PMID 37688464): Researchers characterized enzymatic and serum stability and degradation profiles of GHRP and GHRH-related peptides to build in-house reference standards.
20. Frontiers in Endocrinology, 2026 (PMID 42395176): Reviews performance-enhancing peptides modulating the GH-IGF-1 axis and the gap between clinical evidence and patient self-administration.
21. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions of therapeutic peptides in orthopaedics, including GHRH-class compounds.
22. Sports Medicine, 2026 (PMID 41966639): Evaluates safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance.
23. Annals of Translational Medicine, 2021 (PMID 33842627): Exploratory paper proposes sermorelin as a potentially effective drug for patients with recurrent glioma, a narrow research context unrelated to typical GH-support use.
24. Drug Testing and Analysis, 2016 (PMID 26456392): Investigation found falsified antibiotics and biopharmaceutical injectables circulating in Europe, illustrating real supply-chain quality risk for injectable products.